—
Rising incidences of Cancer, ESRD (End Stage Renal Disease), and HIV have largely contributed to the overwhelming demand for EPO drugs. Approximately 20% of the patients suffering from Cancer/HIV and 70% of the patients suffering from ESRD undergo chemotherapy, which induces anemia in such patients, requiring EPO treatment. Despite this, the market nevertheless witnesses restraints due to highly priced EPO drugs resulting in minimal adoption. However, commercialization of EPO biosimilars would eventually ease the influence of restraints and fuel the market growth, primarily across the developing regions.According to a new report published by Allied Market Research, titled, “erythropoietin drugs market by type, application: global opportunity analysis and industry forecast, 2021–2028," the global erythropoietin drugs market size was valued at $9,243.12 million in 2020, and is projected to reach $14,414.59 million by 2028, registering a CAGR of 5.7% from 2021 to 2028.
Growth of the market is driven by rise in number of treatment cycles for chemotherapy and increase in number cases including cancer,HIV, kidney diseases, and anemia.
Rise in prevalence of anemic conditions induced from end stage renal disease treatment, chemotherapy, and antiretroviral treatment (ART). Hence, rise in number of treatment cycles for chemotherapy and increase in incidences of end stage renal diseases (dialysis) has increased demand for EPO. Side effects associated with EPO including arterial hypertension, iron deficiency, and influenza-like syndrome and longer duration of EPO treatment (4-6 weeks) restrain growth of the erythropoietin drugs market. In addition, rise in trends of commercialization for erythropoietin biosimilars, readily available reimbursements, favorable government regulations, and increase in level of awareness regarding benefits of EPO therapeutics boost growth of the erythropoietin drugs market.
Download Report Sample PDF @ https://www.alliedmarketresearch.com/request-sample/59
Key findings of the study:
Europe led the global EPO drug market in 2013 closely followed by North AmericaAsia Pacific EPO drugs market is projected to grow at a CAGR of 13.3% during the forecast period, fastest among the four geographies.
Currently, Anemia therapeutics (Cancer and HIV treatment) market leads the overall EPO drugs market; however, kidney therapeutic segment would emerge as the largest market segment by 2020.
Originator companies are investing in R&D for expanding product i.e. EPO drug applications to newer disorders such as neural diseases and in wound healing.
EPO drugs market is witnessing high commercialization of biosimilars for the ‘off-patent’ drug namely Erythropoietin alfa.
The first EPO drug – Epogen (Erythropoietin alfa), launched by Amgen, has witnessed patent expiry in 2014. Following this, a number of biosimilar Erythropoietin alfa have been launched by major companies such as Biocon, Ranbaxy, Emcure Pharmaceuticals. In addition, Amgen currently owns the patent Aranesp for Darbepoetin alfa; which is expected to expire by 2016, thus, calling for launch of Darbepoetin Alfa biosimilars. Some of leading players operating in EPO drug market are Amgen Inc., Johnson & Johnson, Roche, LG Life Sciences Ltd., Biocon, Intas Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Ranbaxy Laboratories Ltd., and Celltrion, Inc.
For Purchase Enquiry @ https://www.alliedmarketresearch.com/purchase-enquiry/59
North America dominates the global erythropoietin drugs market, owing to presence of several approved and commercialized erythropoietin biosimilars. However, Asia-Pacific is characterized by presence of generic epoetin products. Asia-Pacific and LAMEA offer promising growth opportunities for erythropoietin manufacturers as these regions are less explored for erythropoietin drugs as compared to North America and Europe.
Contact Info:
Name: David Correa
Email: Send Email
Organization: Allied Market Research
Address: 5933 NE Win Sivers Drive #205, Portland, OR 97220 United States
Phone: 1-800-792-5285
Website: https://www.alliedmarketresearch.com/
Release ID: 89035061
Google
RSS